NCT03515213

Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of California, Irvine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to study the safety and efficacy of fenofibrate, an FDA-approved drug for high cholesterol and/or elevated triglycerides (fats), as a treatment for Huntington's disease (HD). Subjects who meet the entry criteria will be randomized (3:1) to either 145mg of fenofibrate or placebo.

Conditions

• Huntington Disease

Interventions

Type	Name	Description
DRUG	Fenofibrate	145mg of fenofibrate
DRUG	Placebo	Placebo

Timeline

• Start date: 2017-04-27
• Primary completion: 2021-08-31
• Completion: 2021-08-31
• First posted: 2018-05-03
• Last updated: 2023-09-28
• Results posted: 2023-09-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study